Proximagen Group plc is a biotechnology company. The Company focuses on the development and commercialization of novel therapeutics for disorders of the central nervous system, inflammation and oncology. The Company is developing therapeutics in its core disease areas, including epilepsy, Parkinson�s disease, and Alzheimer�s disease, as well as in other areas, such as inflammation, oncology and neuropathic pain. During the year ended December 31, 2011, the Company was in the advancement of naluzotan (a selective 5-HT1a agonist) into the clinic for the treatment of refractive epilepsy. The Company�s three drug candidates are in active clinical trials, which include tonabersat, naluzotan and VAP-1. During 2011, the Company had four clinical stage programs and 11 earlier stage programs, giving a total of 15 programs. Its subsidiaries include Proximagen Limited, Cambridge Biotechnology Limited, Minster Research Limited and Minster Pharmaceuticals plc.